Replies to post #63239 on Biotech Values

[masterlongevity]

A lot of analysts changes their approval prediction from around 70% to 40% following AAN, based on the safety events seen. I would say this drops it even furhter.

Certainly this is not going to be the mega blockbuster once predicted.

[DewDiligence]

Update on FTY720 and the new oral therapies
for MS (from Nature Biotechnology):

#msg-31515145